A randomized phase II study of weekly nab-paclitaxel plus gemcitabine or simplified LV5FU2 as first-line therapy in patients with metastatic pancreatic cancer: the AFUGEM GERCOR trial

BACKGROUND: Metastatic pancreatic adenocarcinoma (PAC) prognosis remains dismal and gemcitabine monotherapy has been the standard treatment over the last decade. Currently, two first-line regimens are used in this setting: FOLFIRINOX and nab-paclitaxel plus gemcitabine. Increasing translational data...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:BMC Cancer
Main Authors: Bachet, Jean-Baptiste, Chibaudel, Benoist, Bonnetain, Franck, Validire, Pierre, Hammel, Pascal, André, Thierry, Louvet, Christophe
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2015
Assuntos:
Study Protocol
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4596389/
https://ncbi.nlm.nih.gov/pubmed/26445094
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-015-1656-4
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados